Literature DB >> 20161051

FDG PET in Prostate Cancer.

Hossein Jadvar.   

Abstract

Entities:  

Year:  2009        PMID： 20161051      PMCID： PMC2746691          DOI： 10.1016/j.cpet.2009.05.002

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


× No keyword cloud information.
  51 in total

1.  Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.

Authors:  Jenalle D Chandler; Elizabeth D Williams; John L Slavin; James D Best; Suzanne Rogers
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

2.  Molecualr imaging of cancer: from molecules to humans. Introduction.

Authors:  Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

3.  [Technical limits of PET/CT with 18FDG in prostate cancer].

Authors:  D von Mallek; B Backhaus; S C Müller; A Matthies; H Palmedo; U Jaeger; H-J Biersack; M Reinhardt
Journal:  Aktuelle Urol       Date:  2006-05       Impact factor: 0.658

4.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.

Authors:  C Hofer; C Laubenbacher; T Block; J Breul; R Hartung; M Schwaiger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.

Authors:  Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch
Journal:  Nucl Med Biol       Date:  2002-11       Impact factor: 2.408

6.  Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.

Authors:  Toshihiko Hara; Aditya Bansal; Timothy R DeGrado
Journal:  Nucl Med Biol       Date:  2006-10-04       Impact factor: 2.408

7.  Glucose metabolism of human prostate cancer mouse xenografts.

Authors:  Hossein Jadvar; Li Xiankui; Antranik Shahinian; Ryan Park; Michel Tohme; Jacek Pinski; Peter S Conti
Journal:  Mol Imaging       Date:  2005 Apr-Jun       Impact factor: 4.488

Review 8.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

Review 9.  Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function.

Authors:  John E Wilson
Journal:  J Exp Biol       Date:  2003-06       Impact factor: 3.312

10.  Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.

Authors:  E C S C Etchebehere; H A Macapinlac; M Gonen; K Humm; H W D Yeung; T Akhurst; H I Scher; S M Larson
Journal:  Q J Nucl Med       Date:  2002-06
View more
  16 in total

1.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 2.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 3.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

4.  Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT.

Authors:  Hossein Jadvar; Erik M Velez; Bhushan Desai; Lingyun Ji; Patrick M Colletti; David I Quinn
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

5.  GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

Authors:  Salma Meziou; Cassandra Ringuette Goulet; Hélène Hovington; Véronique Lefebvre; Étienne Lavallée; Michelle Bergeron; Hervé Brisson; Audrey Champagne; Bertrand Neveu; Didier Lacombe; Jean-Mathieu Beauregard; François-Alexandre Buteau; Julie Riopel; Frédéric Pouliot
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-01-13       Impact factor: 5.554

Review 6.  Molecular imaging of prostate cancer.

Authors:  Josef J Fox; Heiko Schöder; Steven M Larson
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

7.  Incidental Focal (18)F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria.

Authors:  Suk Kyong Cho; Joon Young Choi; Jang Yoo; Miju Cheon; Ji Young Lee; Seung Hyup Hyun; Eun Jeong Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-07-06

8.  Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.

Authors:  Joe H Chang; Daryl Lim Joon; Sze Ting Lee; Chee-Yan Hiew; Stephen Esler; Sylvia J Gong; Morikatsu Wada; David Clouston; Richard O'Sullivan; Yin P Goh; Henri Tochon-Danguy; J Gordon Chan; Damien Bolton; Andrew M Scott; Vincent Khoo; Ian D Davis
Journal:  Eur Radiol       Date:  2013-11-06       Impact factor: 5.315

9.  Utility of FDG-PET in clinical neuroendocrine prostate cancer.

Authors:  Daniel E Spratt; Somali Gavane; Lisa Tarlinton; Shoaib B Fareedy; Michael G Doran; Michael J Zelefsky; Joseph R Osborne
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

10.  Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  Miles P Mannas; Taeweon Lee; Maral Pourghiasian; Don C Wilson; Peter C Black
Journal:  Can Urol Assoc J       Date:  2019-11-29       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.